MAS1 has been shown to counteract the angiotensin II receptor type 1 (AGTR1)‐mediated signaling pathway in RAS on multiple physiological systems,[13] including malignant tumors.[8] Recent evidence suggests that the inhibitory activity induced by MAS1 against AGTR1 may be independent of the proposed endogenous ligand Ang 1–7.[14] Thus, we investigated how the increase in MAS1 levels might counteract AGTR1 activation in a ligand‐independent manner. The gene discussed is MAS1; the disease is cancer.